share_log

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES

DelveInsight預測,到2032年,針對急性淋巴細胞白血病的CAR T細胞療法市場將實現驚人的增長 | 主要公司-AUTOLUS THERAPEUTICS、CELLECTIS、WUGEN、SERVIER、ALLOGENE、PRECISION BIOSCIENCES
PR Newswire ·  05/23 05:30

The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-CART-007, UCART19, PBCAR0191, AUTO1/22, and others, its promising efficacy in treating refractory and relapsed cases. With ongoing research, expanding clinical trials, and increasing approvals, the market is set to witness a surge in adoption, offering renewed hope for patients battling this aggressive form of leukemia.

在預期推出的OBECABTAGENE AUTOLEUCEL(OBE-CEL)、UCART22、WU-CART-007、UCART19、PBCAR0191、AUTO1/22等療法及其治療難治性和復發病例方面的良好療效的推動下,急性淋巴細胞白血病的CAR T細胞療法市場有望實現大幅增長。隨着研究的持續進行、臨床試驗的擴大和批准的增加,市場的採用率將激增,這爲與這種侵略性白血病作鬥爭的患者帶來了新的希望。

LAS VEGAS, May 22, 2024 /PRNewswire/ -- DelveInsight's CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-Cell therapy for ALL emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan].

拉斯維加斯,2024 年 5 月 22 日 /PRNewswire/ — DelveInsight's 急性淋巴細胞白血病的 CAR T 細胞療法市場洞察 報告包括對當前治療實踐、所有新興藥物的CAR T細胞療法、個體療法的市場份額以及2019年至2032年當前和預測的市場規模的全面了解,細分爲7MM [美國、歐盟四國(德國、法國、意大利和西班牙)以及英國和日本]。

Key Takeaways from the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Report

《急性淋巴細胞白血病的CAR T細胞療法市場報告》的關鍵要點

  • According to DelveInsight's analysis, the market size for CAR T-Cell therapy for ALL reached USD 75 million in 2021 across the 7MM.
  • In the 7MM, the US accounted for the largest market size in 2021, with approximately USD 55 million.
  • DelveInsight's analysis reveals that the total incident cases of ALL in the US comprised ~6,200 in 2021.
  • Leading CAR T-Cell therapy for ALL companies such as AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES, and others are developing novel CAR T-Cell therapies for NHL drugs that can be available in the CAR T-Cell therapy for ALL market in the coming years.
  • Promising CAR T-Cell therapies for NHL in the pipeline include OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-CART-007, UCART19, PBCAR0191, AUTO1/22, and others.
  • CAR-T cells provide a long-term benefit with a one-time treatment, avoiding the toxicity of salvage chemotherapy and autologous transplant for patients with high-risk illnesses. The approvals have altered the standard of care for high-risk patients who are either primary refractory or have early recurrence following front-line therapy.
  • 根據DelveInsight的分析,針對ALL的CAR T細胞療法的市場規模已達到 7,500 萬美元 2021 年跨越 7MM。
  • 在700萬美元中,美國在2021年佔最大的市場規模,約爲 5,500 萬美元。
  • DelveInsight的分析顯示,美國急性呼吸綜合徵的總事故病例包括 ~6,200 在 2021 年。
  • 爲所有公司提供領先的 CAR T 細胞療法,例如 AUTOLUS 療法、CELLECTIS、WUGEN、SERVIER、異基因、精準生物科學,其他公司正在開發用於NHL藥物的新型CAR T細胞療法,這些療法將在未來幾年內在針對ALL的CAR T細胞療法市場上市。
  • 正在研發的 NHL 有前途的 CAR T 細胞療法包括 OBECABTAGENE AUTOLEUCEL(OBE-CEL)、UCART22、WU-CART-007、UCART19、PBCAR0191、AUTO1/22和其他人。
  • CAR-T細胞通過一次性治療提供長期益處,避免了挽救性化療和自體移植對高危疾病患者的毒性。這些批准改變了原發性難治性或一線治療後早期復發的高危患者的護理標準。

Discover which therapies are expected to grab the major CAR T-Cell therapy for ALL market share @ CAR T-Cell therapy for ALL Market Report

了解哪些療法有望奪取主要的CAR T細胞療法以獲得所有市場份額 @ 全民CAR-T細胞療法市場報告

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Overview

急性淋巴細胞白血病的 CAR T 細胞療法概述

Acute lymphocytic leukemia (ALL), alternatively known as acute lymphoblastic leukemia, is a form of cancer impacting the blood and bone marrow. It originates from immature white blood cells, or lymphocytes, found in the bone marrow. This condition is characterized by an excess production of these immature cells, referred to as lymphoblasts or leukemic blasts. Consequently, the bone marrow fails to produce sufficient red blood cells, normal white blood cells, and platelets, leading to increased vulnerability to anemia, recurrent infections, and easy bruising and bleeding. The leukemic blasts can escape from the bone marrow into the bloodstream and accumulate in various organs such as the lymph nodes, spleen, liver, and central nervous system (including the brain and spinal cord). Diagnostic methods for ALL typically involve blood tests, bone marrow examinations, imaging procedures, and analysis of spinal fluid.

急性淋巴細胞白血病(ALL),也稱爲急性淋巴細胞白血病,是一種影響血液和骨髓的癌症。它起源於骨髓中發現的未成熟的白細胞或淋巴細胞。這種情況的特徵是這些未成熟細胞的過量產生,這些細胞被稱爲淋巴細胞或白血病細胞。因此,骨髓無法產生足夠的紅細胞、正常的白細胞和血小板,從而增加患貧血、反覆感染以及容易出現瘀傷和出血的脆弱性。白血病細胞可以從骨髓逃出到血液中,積聚在淋巴結、脾臟、肝臟和中樞神經系統(包括大腦和脊髓)等各種器官中。急性淋巴細胞白血病的診斷方法通常包括血液檢查、骨髓檢查、影像學檢查和脊髓液分析。

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Epidemiology Segmentation

急性淋巴細胞白血病的 CAR T 細胞療法流行病學細分

Among the gender-specific cases, males accounted for nearly 3,500 cases, while females accounted for 2,700 in the US in 2021. Among the type-specific cases of ALL, the incident cases of B-ALL accounted for nearly 85%, while that of T-ALL accounted for nearly 15% in the US.

在按性別劃分的案例中,男性幾乎佔比 3,500 病例,而女性佔 2,700 2021 年在美國。在急性淋巴細胞白血病的特定類型病例中,B-ALL的事件病例幾乎佔了上風 85%,而 T-ALL 的佔比差不多 15% 在美國。

The CAR T-Cell therapy for ALL market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: total incident cases of ALL, gender-specific cases of ALL, age-specific cases of ALL, subtype-specific cases of ALL, genetic-mutation specific cases of ALL, and total treated cases of ALL

針對所有人群的CAR T細胞療法市場報告提供了2019-2032年研究期的7MM流行病學分析,細分爲: 急性淋巴細胞白血病發病總數、按性別分列的急性淋巴細胞白血病病例、ALL 的特定亞型病例、ALL 的基因突變特異性病例和急性淋巴細胞白血病的治療病例總數

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Treatment Market

急性淋巴細胞白血病治療市場的 CAR T 細胞療法

For years, conventional chemotherapy containing cytotoxic agents has served as the primary treatment approach for adults with ALL. However, this method poses significant risks including potentially fatal complications such as infection, bleeding, thrombosis, neuropathy, osteonecrosis, and the development of secondary cancers like AML and MDS.

多年來,含有細胞毒性藥物的傳統化療一直是成人急性淋巴細胞白血病的主要治療方法。但是,這種方法存在重大風險,包括潛在的致命併發症,例如感染、出血、血栓形成、神經病變、骨壞死以及急性髓細胞白血病和多發性硬化症等繼發性癌症的發展。

The landscape shifted dramatically with the introduction of CAR-T cell therapy over a decade ago, initially successful in treating pediatric ALL. Since then, there has been an explosion of research into new CAR-T constructs and targets, as well as a deeper understanding of CAR T-cell persistence and novel mechanisms of antigen escape.

十多年前,隨着CAR-T細胞療法的推出,格局發生了巨大變化,該療法最初成功治療了兒科急性淋巴細胞白血病。從那時起,對新的CAR-T結構和靶標的研究激增,對CAR T細胞的持久性和抗原逃逸的新機制也有了更深入的了解。

This evolution saw the approval of KYMRIAH (tisagenlecleucel, or tisa-cel, by Novartis) for pediatric and young adult patients who had undergone at least two prior lines of therapy, followed by TECARTUS (brexucabtagene autoleucel, or brexu-cel, by Kite) for adults experiencing their first relapse. CAR-T cell therapy is poised to catalyze the next significant advancement in leukemia immunotherapy.

這種演變得到了... 的認可 KYMRIAH(諾華出品的 tisagenlecleucel 或 tisa-cel) 針對之前至少接受過兩輪治療的兒科和年輕成年患者,其次是 TECARTUS(Kite 的 brexucabtagene autoleucel 或 brexu-cel) 適用於首次復發的成年人。CAR-T細胞療法有望催化白血病免疫療法的下一個重大進展。

TECARTUS, an immunotherapy, is developed to target CD19-presenting cancer and normal B cells, altering one's T cells genetically for the task. Studies have unveiled that once these modified T cells engage with CD19-presenting cells, specific domains like CD28 and CD3-zeta kickstart signaling processes, activating the T cells, prompting their multiplication, empowering them with effective capabilities, and inducing the release of inflammatory agents. This orchestrated series of actions culminate in the elimination of CD19-expressing cells. In October 2021, the FDA sanctioned TECARTUS for adults with refractory or relapsed B-ALL. Similarly, the European Commission approved it in September 2022.

TECARTUS,一種免疫療法,旨在靶向呈遞CD19的癌症和正常的B細胞,通過基因改變人們的T細胞來完成這項任務。研究表明,一旦這些經過修飾的T細胞與呈遞CD19的細胞相互作用,CD28和CD3-Zeta等特定結構域就會啓動信號傳導過程,激活T細胞,促進其增殖,賦予其有效能力,並誘導炎症劑的釋放。這一系列精心策劃的行動最終消滅了表達 CD19 的細胞。2021 年 10 月,美國食品藥品管理局批准了針對難治性或複發性 B-ALL 的成年人使用 TECARTUS。同樣,歐盟委員會於2022年9月批准了該法案。

KYMRIAH is an immunotherapy method that directs T cells toward CD19-expressing cells, both cancerous and healthy, through genetic modification. This involves modifying a patient's T cells with a gene that encodes a chimeric antigen receptor (CAR), which can identify and remove CD19-expressing cells. The CAR contains a fragment of a mouse antibody that targets CD19 and is connected to signaling parts inside the cell. When the CAR binds to CD19 on cells, it triggers a series of actions that lead to the expansion, activation, elimination of target cells, and persistence of the modified T cells. KYMRIAH gained approval from the US FDA in August 2017 for treating patients up to 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Subsequent approvals were obtained from the European Commission in August 2018 and the Ministry of Health, Labour and Welfare in Japan in March 2019.

KYMRIAH 是一種免疫療法,通過基因改造將T細胞引向表達CD19的細胞,包括癌細胞和健康細胞。這包括使用編碼嵌合抗原受體(CAR)的基因修改患者的T細胞,該基因可以識別和去除表達CD19的細胞。CAR 包含靶向 CD19 的小鼠抗體片段,該片段與細胞內部的信號傳導部分相連。當 CAR 與細胞上的 CD19 結合時,它會觸發一系列作用,從而擴展、激活、消滅靶細胞,並使改性 T 細胞持續存在。KYMRIAH於2017年8月獲得美國食品藥品管理局的批准,用於治療25歲以下的復發或難治性B細胞急性淋巴細胞白血病(R/R B-ALL)患者。隨後於2018年8月獲得歐盟委員會的批准,並於2019年3月獲得日本厚生、勞動和福利部的批准。

To know more about CAR T-Cell therapy for ALL treatment guidelines, visit @ CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Management

要了解有關適用於 ALL 的 CAR T 細胞療法治療指南的更多信息,請訪問 @ 用於急性淋巴細胞白血病管理的 CAR T 細胞療法

Emerging CAR T-Cell Therapies for NHL and Key Companies

適用於 NHL 和主要公司的新興 CAR T 細胞療法

  • OBECABTAGENE AUTOLEUCEL (OBE-CEL): AUTOLUS THERAPEUTICS
  • UCART22: CELLECTIS
  • WU-CART-007: WUGEN
  • UCART19: CELLECTIS/SERVIER/ALLOGENE
  • PBCAR0191: PRECISION BIOSCIENCES
  • AUTO1/22: AUTOLUS THERAPEUTICS
  • OBECABTAGENE AUTOLEUCEL(OBE-CEL):AUTOLUS 療法
  • UCART22:CELLECTIS
  • WU-CART-007: UGEN
  • UCART19: CELLECTIS/SERVICE/ALLOGENE
  • PBCAR0191:精準生物科學
  • AUTO1/22:AUTOLUS 療法

Learn more about the FDA-approved CAR T-Cell therapy for ALL @ Drugs for CAR T-Cell therapy for ALL Treatment

了解有關經美國食品藥品管理局批准的針對所有人的 CAR T 細胞療法的更多信息 @ 用於 CAR T細胞療法的藥物,用於急性淋巴細胞治療

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Dynamics

急性淋巴細胞白血病的 CAR T 細胞療法市場動態

CAR T-cell therapy has revolutionized the treatment landscape for acute lymphoblastic leukemia, introducing a paradigm shift in cancer therapy. The market dynamics for CAR T-cell therapy in ALL are marked by a delicate balance of innovation, accessibility, and affordability. Despite its remarkable efficacy, challenges persist, primarily concerning its high cost and logistical complexities, which impact market penetration and patient access.

CAR T細胞療法徹底改變了急性淋巴細胞白血病的治療格局,引入了癌症治療的模式轉變。急性淋巴細胞療法中CAR-T細胞療法的市場動態以微妙爲標誌 創新、可訪問性和可負擔性的平衡。儘管其功效顯著,但挑戰仍然存在,主要與其有關 成本高,物流複雜,這會影響市場滲透率和患者准入。

The dynamic interplay between pharmaceutical companies, healthcare providers, and regulatory bodies shapes the trajectory of the CAR T-cell therapy market for ALL. Pharmaceutical companies are engaged in fierce competition to develop novel therapies with enhanced efficacy and safety profiles while navigating regulatory pathways for approvals. Simultaneously, healthcare providers are tasked with optimizing treatment protocols, managing adverse events, and ensuring equitable access to this cutting-edge therapy for eligible patients.

之間的動態相互作用 製藥公司、醫療保健提供商和監管機構 塑造了ALL的CAR T細胞療法市場的發展軌跡。製藥公司從事 開發新療法的激烈競爭 提高療效和安全性,同時探索監管途徑以獲得批准。同時,醫療保健提供者的任務是 優化治療方案,管理不良事件,並確保符合條件的患者公平獲得這種尖端療法。

The evolving landscape of reimbursement policies and healthcare infrastructures further influences market dynamics. Efforts to secure reimbursement and streamline distribution channels are pivotal for enhancing the adoption of CAR T-cell therapy in ALL. As stakeholders collaborate to address these challenges, the market for CAR T-cell therapy continues to evolve, driven by a shared commitment to improving patient outcomes and advancing the standard of care for ALL.

不斷變化的格局 報銷政策和醫療基礎設施 進一步影響市場動態。努力實現 確保報銷安全並簡化分銷渠道 對於促進 CAR T 細胞療法在急性淋巴細胞治療中的採用至關重要。隨着利益相關者合作應對這些挑戰,CAR T細胞療法市場在改善患者預後和提高ALL護理標準的共同承諾的推動下繼續發展。

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Size in 2021

USD 75 Million

Key CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Companies

AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES, and others

Key CAR T-Cell Therapy for Acute Lymphoblastic Leukemia in Pipeline

OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-CART-007, UCART19, PBCAR0191, AUTO1/22, and others

急性淋巴細胞白血病的 CAR T 細胞療法市場報告指標

細節

學習週期

2019—2032

覆蓋範圍

7MM [美國、歐盟四國(德國、法國、意大利和西班牙)、英國和日本]。

2021 年急性淋巴細胞白血病的 CAR T 細胞療法市場規模

7,500 萬美元

急性淋巴細胞白血病公司的關鍵 CAR T 細胞療法

AUTOLUS THERAPEUTICS、CELLECTIS、WUGEN、SERVIER、ALLOGENE、精準生物科學等

治療急性淋巴細胞白血病的關鍵 CAR T 細胞療法正在研發中

OBECABTAGENE AUTOLEUCEL (OBE-CEL)、UCART22、WU-CART-007、UCART19、PBCAR0191、AUTO1/22 等

Scope of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Report

的範圍 急性淋巴細胞白血病的 CAR T 細胞療法 市場報告

  • Therapeutic Assessment: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia current marketed and emerging therapies
  • CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Access and Reimbursement
  • 治療評估: 針對急性淋巴細胞白血病的 CAR T 細胞療法,當前上市的和新興的療法
  • 急性淋巴細胞白血病的 CAR T 細胞療法 市場動態: 急性淋巴細胞白血病藥物新興CAR T細胞療法的關鍵市場預測假設和市場前景
  • 競爭情報分析: SWOT 分析、聯合分析和市場進入策略
  • 未滿足的需求、KOL的觀點、分析師的觀點、急性淋巴細胞白血病的CAR T細胞療法市場準入和報銷

Discover more about CAR T-Cell therapy for ALL drugs in development @ CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Clinical Trials

了解有關針對所有在研藥物的 CAR T 細胞療法的更多信息 @ 用於急性淋巴細胞白血病臨床試驗的 CAR T 細胞療法

Table of Contents

目錄

1

KEY INSIGHTS

2

REPORT INTRODUCTION

3

EXECUTIVE SUMMARY OF CAR-T IN ALL

4

KEY EVENTS

5

EPIDEMIOLOGY AND MARKET METHODOLOGY

6

CAR-T IN ALL MARKET OVERVIEW AT A GLANCE

7

DISEASE BACKGROUND AND OVERVIEW

8

CURRENT TREATMENT PRACTICES: ALL

9

EPIDEMIOLOGY AND PATIENT POPULATION OF 7MM

10

PATIENT JOURNEY

11

MARKETED DRUGS

12

EMERGING DRUGS

13

CAR-T IN ALL: THE 7MM ANALYSIS

14

UNMET NEEDS

15

SWOT ANALYSIS

16

KOL VIEWS

17

MARKET ACCESS AND REIMBURSEMENT

18

APPENDIX

19

DELVEINSIGHT CAPABILITIES

20

DISCLAIMER

21

ABOUT DELVEINSIGHT

1

關鍵見解

2

報告簡介

3

總而言之 CAR-T 的內容提要

4

關鍵事件

5

流行病學和市場方法

6

CAR-T 在所有市場概覽一覽

7

疾病背景和概述

8

目前的治療方法:全部

9

流行病學和患者群體 7MM

10

患者旅程

11

上市的藥物

12

新興藥物

13

總而言之 CAR-T:7MM 分析

14

未滿足的需求

15

SWOT 分析

16

KOL 觀點

17

市場準入和報銷

18

附錄

19

DELVEINSIGHT能力

20

免責聲明

21

DELVEINSIGHT

Related Reports

相關報道

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline

用於急性淋巴細胞白血病管道的 CAR T 細胞療法

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-Cell therapy for ALL companies, including Autolus, PersonGen Biotherapeutics, Pepromene Bio, Inc., Actinium Pharmaceuticals, among others.

急性淋巴細胞白血病的 CAR T 細胞療法管道洞察 — 2024 報告提供了有關所有公司的管道格局、管道藥物概況(包括臨床和非臨床階段產品)以及關鍵的CAR T細胞療法的全面見解,包括 Autolus、personGen Biotherapeutics、Pepromene Bio, Inc.、Actinium Pharmicals、 除其他外。

CAR T-Cell Therapy Market

CAR T 細胞療法市場

CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, among others.

CAR T細胞療法市場洞察、流行病學和市場預測— 2032 報告深入了解了該疾病、歷史和預測的流行病學,以及市場趨勢、市場驅動因素、市場壁壘和主要的CAR T細胞療法公司,包括 CytoAgents、基因泰克、Incyte Corporation、Caribou Biosciences、Chimeric Therapeutics、Allogene Therapeutics、iCell Gene Therapeutics、Synthekine、Janssen 研究與開發、SecuraBio、Impact Bio、A2 生物療法、Gracell 生物製藥、Wugen、薩那生物科技、Oncternal Therapeutics、Vor Biopharma、CarsPharma Gen Therapeutics、Autolus Limited、Arcellx、Kite、諾華、Lyell Immunopharma、Impact Bio、Tmunity Therapeutics、Poseida Therapeutics、Precigen、AffyImmune Therapeutics、2seventy bio、武田、Cartesian Therapeutics、Cabaletta生物、傳奇生物、Miltenyi Biomedicine、Beam Therapeutics、 除其他外。

CAR T-Cell Therapy Competitive Landscape

CAR T 細胞療法的競爭格局

CAR T-cell Therapy Competitive Landscape – 2024 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.

CAR T 細胞療法競爭格局 — 2024 報告提供了有關研發渠道和當前格局、上市藥物概況以及主要的CAR T細胞療法公司的全面見解,包括 Alnylam製藥、JW Therapeutics、吉利德科學、楊森製藥、信達生物製藥、索倫託療法、笛卡爾療法、CASI製藥、尤文塔斯細胞療法、諾華、波塞達療法、上海優尼卡療法生物醫學科技、華生威細胞療法、武漢百瑞生物科技、密爾騰生物醫學、百時美施貴寶,Autolus Limited、北京ImmunoChina醫療科技、卡斯金藥業、細胞生物醫學集團、重慶精準生物科技、尤里卡療法、方程製藥、廣州生物基因科技、河北森朗生物科技、野馬生物、MolMed、Aurora BioPharma、Autorus、Bellicum 製藥、Kecellitics 生物技術公司、雅克生物科技、密涅瓦生物科技、異基因療法、PersonGen Biotherapeutics(蘇州)、精準生物科學、Pregene(深圳)生物技術公司、上海基因化學、上海隆耀生物科技、深圳博耀生物科技 Indebio,除其他外。

Acute Lymphocytic Leukemia Market

急性淋巴細胞白血病市場

Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute lymphocytic leukemia companies, including Novartis AG, Gracell Biotechnologies, Pfizer, Bristol-Myers Squibb, Hebei Senlang Biotechnology, PersonGen BioTherapeutics (Suzhou) Co Ltd., among others.

急性淋巴細胞白血病市場洞察、流行病學和市場預測— 2032 報告深入了解了該疾病、歷史和預測的流行病學,以及市場趨勢、市場驅動因素、市場壁壘和主要的急性淋巴細胞白血病公司,包括 諾華股份公司、格雷賽爾生物科技、輝瑞、百時美施貴寶、河北森朗生物科技、PersonGen Biotherapeutics(蘇州)有限公司、 除其他外。

About DelveInsight

DelveInsight簡介

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsight 是一家專注於生命科學的領先商業顧問和市場研究公司。它通過提供全面的端到端解決方案來提高製藥公司的績效,從而爲製藥公司提供支持。通過我們的訂閱平台 PharmDelve 輕鬆訪問所有醫療保健和製藥市場研究報告

Contact Us
Shruti Thakur
[email protected]
+14699457679

聯繫我們
Shruti Thakur
[電子郵件保護]
+14699457679

Logo:

徽標:

SOURCE DelveInsight Business Research, LLP

來源 DelveInsight 商業研究有限責任公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論